MDGL | Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Lowered by Zacks Investment Research

Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday, reports.According to Zacks, “Madrigal Pharmaceuticals, engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases.Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist […]Dispatch Tribunal